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Capsule summary (50 words max)55
 What is already known on this topic56
Pyoderma gangrenosum is a painful ulcerating disease. The current evidence base for treatment is57
very limited.58
59
 What this article adds to our knowledge60
This prospective cohort study of topical therapies included 66 participants and is the largest study to61
date.62
63
 How this info impacts clinical practice64
Topical therapies appear effective for patients with mild disease, but not all patients respond and65
recurrence is common.66
67
3Abstract68
Background: pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for69
treatment.70
Objective: to estimate the effectiveness of topical therapies in the treatment of PG.71
Methods: prospective cohort study of UK secondary care patients with a clinical diagnosis of PG suitable for72
topical treatment (recruited July 2009 to June 2012). Participants received topical therapy following normal73
clinical practice (mainly Class I-III topical corticosteroids, tacrolimus 0.03% or 0.1%). Primary outcome: speed74
of healing at 6 weeks. Secondary outcomes: proportion healed by 6 months; time to healing; global75
assessment; inflammation; pain; quality-of-life; treatment failure and recurrence.76
Results: Sixty-six patients (22 to 85 years) were enrolled. Clobetasol propionate 0.05% was the most commonly77
prescribed therapy. Overall, 28/66 (43.8%) of ulcers healed by 6 months. Median time-to-healing was 145 days78
(95% CI: 96 days,∞). Initial ulcer size was a significant predictor of time-to-healing (hazard ratio 0.94 (0.88;79
1.00); p = 0.043). Four patients (15%) had a recurrence.80
Limitations: No randomised comparator81
Conclusion: Topical therapy is potentially an effective first-line treatment for PG that avoids possible side-82
effects associated with systemic therapy. It remains unclear whether more severe disease will respond83
adequately to topical therapy alone.84
85
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5Introduction95
Pyoderma Gangrenosum (PG) is an uncommon, painful ulcerative inflammatory dermatosis that is associated96
with considerable morbidity1, 2 and a reported three-fold increased risk of death3.97
The most commonly prescribed treatments for PG are systemic therapies (e.g. prednisolone, ciclosporin,98
intravenous immunoglobulin or biologic therapies). Nevertheless, topical treatments (e.g. corticosteroids and99
calcineurin inhibitors) have also been recommended for localised disease4, 5 and may be a useful first-line100
therapy for some patients.101
We conducted a multi-centre prospective cohort study to investigate the efficacy of topical therapy as a first-102
line treatment for PG. This cohort study was conducted alongside a randomised controlled trial (RCT) of systemic103
treatments for PG (STOP GAP Trial), in which oral prednisolone was compared to ciclosporin.6104
Our objective was to provide prospectively collected estimates of treatment response for patients receiving105
topical therapy for their PG.106
Methods107
Ethics and regulatory approvals were obtained; participants gave written informed consent. Independent Trial108
Steering Committee and Data Monitoring Committees provided oversight.109
Study design110
Prospective cohort study of patients with a clinical diagnosis of PG, for whom topical therapy was indicated.111
Patients with more severe PG (requiring systemic therapy) were enrolled into the parallel RCT6 but were eligible112
for inclusion in the topical therapy cohort study if systemic therapy was contra-indicated, or if patient preference113
was to receive topical treatment.114
Participants were enrolled for up to 6 months, or until the target PG ulcer had healed. Medications were115
prescribed as per local practice at the recruiting hospital.116
Research questions117
1. What is the typical treatment response in patients for whom topical therapy is indicated?118
2. What proportion of participants require escalation of treatment to systemic medication?119
3. What is the impact of PG on patient-reported quality of life?120
64. What factors predict treatment response?121
Participants122
Recruitment took place in 28 secondary care hospitals throughout the UK. Participants were identified from123
dermatology, rheumatology, gastroenterology and general medicine clinics.124
Participants were aged 18 years or older and had a clinical diagnosis of PG (confirmed by the recruiting125
dermatologist, with biopsy to exclude alternative aetiologies if clinically indicated), and at least one measureable126
ulcer. The decision over whether to treat with topical therapy or not was based on the views of the dermatologist127
in discussion with patients.128
Patients were excluded if they had pustular or granulomatous PG variants (as they may respond differently to129
therapy and measurement of a single ulcer was not possible); if they had received oral prednisolone, ciclosporin130
or intravenous immunoglobulin for the treatment of PG in the previous month, or were participating in another131
clinical trial.132
Ongoing treatment with systemic therapies for the management of underlying co-morbidities (e.g. rheumatoid133
arthritis) was permitted.134
Interventions135
Patients received topically applied interventions for the treatment of PG. The dermatologist was free to136
prescribe whichever therapy and dosage regimen they preferred according to local practice. In the UK, normal137
practice would be to apply topical interventions to the inflammatory edge of the ulcer. Systemic therapies for138
the treatment of PG were prohibited, but were continued if taken for other conditions.139
Assessments and outcomes140
Study visits took place at 2 weeks, 6 weeks and 6 months (or at time of healing if sooner). Other unscheduled141
consultations took place as per normal practice.142
A target lesion was used for outcome assessment. Lesion size was captured by the treating dermatologist based143
on maximal longitudinal length and maximum perpendicular length, converted to area by the formula (length x144
width x 0.785), which approximates an ellipse.145
7Outcomes: i) speed of healing at 6 weeks (primary outcome in-line with RCT primary outcome); ii) proportion146
healed by 6 months; iii) time to healing; iv) global assessment of improvement at 6 weeks and final visit; v)147
inflammation assessment at 6 weeks and final visit7; vi) pain in the first 6 weeks (scored daily 0 to 4); vii)148
quality-of-life (EuroQol 5 Dimensions, 3 Levels – EQ-5D-3L8 & Dermatology Life Quality Index - DLQI9.149
Healing was defined as the point at which dressings were no longer required. This was reported by the150
participants, and a clinic visit was arranged to confirm healing as soon as possible thereafter. In cases where the151
date on which dressings were stopped was unavailable, healing was assumed to have taken place on the day152
that the ulcer was confirmed as healed by the recruiting dermatologist. Pain scores and use of dressings were153
collected using daily diaries.154
Measures taken to control bias155
This was an open study, with no control group. In order to mitigate the risk of bias, consecutive participants156
were enrolled into the study and followed up prospectively. Outcomes were assessed using standard methods157
and clinicians’ and patients’ views were compared where appropriate. Every effort was made to maintain follow-158
up of all participants.159
Sample size160
This was a pragmatic cohort study. No formal sample size calculation was performed, as this was a descriptive161
study without formal between-treatment comparisons.162
Statistical analysis163
The primary analysis included all participants who received at least one topical medication and had available164
data at both the baseline and the 6 week visit. Pre-defined sub-groups were i) participants who received165
clobetasol propionate 0.05%, and ii) participants who received a topical calcineurin inhibitor (tacrolimus or166
pimecrolimus).167
Data are presented descriptively and data relating to participants of the STOP GAP RCT are included alongside168
those of the topical therapy cohort, but no formal comparisons have been made.169
8If a participant received more than one topical medication, they were included in all relevant study populations.170
Participants who withdrew due to lack of treatment response, or who started a systemic medication during the171
period of the study were classed as treatment failures for the topical medication.172
Exploratory analyses adjusting for lesion size at baseline, presence of underlying autoimmune disease, age,173
weight, sex and size of recruiting centre were conducted to determine possible factors associated with174
treatment response. Linear regression models were used for continuous outcomes, logistic regression for binary175
outcomes and cox proportional hazards for time to event outcomes.176
Results177
Participants and treatment allocation178
Recruitment took place between July 2009 and June 2012.179
In total, 67 participants were enrolled in the study, but one was subsequently excluded from the analysis180
having received oral prednisolone for PG (Figure 1).181
Forty-nine (74.2%) participants received clobetasol propionate 0.05% (Dermovate™, GlaxoSmithKline); 10182
(15.2%) received tacrolimus 0.03% or 0.1% (Protopic®; Astellas Pharma); and eight received other topical183
interventions including other topical corticosteroids (n=6), fludroxycortide impregnated tape (Haelan® Tape,184
Typharm) (n=1), and lymecycline (Tetralysal® 300, Galderma) (n=1). One participant received both clobetasol185
propionate and tacrolimus and was therefore included in both sub-groups. Five participants in the clobetasol186
propionate group were taking concurrent anti-inflammatory/immune modifying medications for the treatment187
of other conditions including azathioprine (n = 2), tetracyclines (n = 2) and anti-TNF (n = 1).188
The reason for choosing systemic or topical therapy (and therefore eligibility for the cohort study or the RCT),189
were: topical treatment failure - for those opting for systemic therapy (n=47); features of the disease (n=43);190
and patient’s preference (n=6).191
Details of demographic and baseline characteristics are summarised (Table 1: Baseline characteristics of192
participants in STOP GAP RCT and topical therapies cohort study193
Table 2: Treatment response (RCT participants and observational cohort)194
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200
). The majority of participants were identified through dermatology services (47; 71.2%); others were201
identified from gastroenterology (7; 10.6%), rheumatology (1; 1.5%), general medicine (2.0; 3%) and other202
sources (9; 13.6%).203
Baseline characteristics for participants in the cohort study were broadly similar to those enrolled in the204
parallel RCT, with the exception that the mean lesion size was smaller (4.7cm2 versus 9cm2), the mean number205
of ulcers was lower (1.6 versus 2.4), and fewer participants had had PG previously (18% versus 31%) (Table 1).206
Adherence to medication207
Only 12/66 (18.2%) participants provided data on adherence to their prescribed treatments at the end of the208
study. Nevertheless, the levels of treatment response achieved would suggest that the participants were using209
their medications broadly as prescribed. Nine participants in the clobetasol propionate group used systemic210
medication for comorbidities during the study (azathioprine n=2; anti-TNF n=1; tetracyclines n=2).211
Treatment response212
Details of the clinical outcomes are summarised (Table 2).213
Mean speed of healing was -0.1 cm2 per day (SD 0.3). This is approximately half that observed in the RCT patients214
receiving systemic therapy, but the method of assessment was different for the two studies (physical215
measurements by clinician versus planimetry from digital images), and so direct comparison is difficult. The216
mean change from baseline in area of the lesion at the final visit was –4.2 (SD 11.5)cm2, with similar changes217
reported in the clobetasol and tacrolimus sub-groups (–4.0 (SD 11.9) and –3.9 (SD 6.0), respectively).218
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Overall, 28 (43.8%) participants healed on topical therapy alone within the 6-month study period. Twenty two219
(33.3%) required systemic therapy, and of these 13 (59.1%) went on to be enrolled into the RCT (Figure 1). For220
those that entered the RCT, 8 (61.5%) healed by 6 months, with 3 of the 13 (23.1%) healing by 6 weeks.221
Ulcers healed in a median duration of 145 days (95% CI: 96 days,∞) (Table 2, Figure 2). Cox proportional hazards222
model suggested that size of initial lesion was an important predictive factor in determining time to healing (HR223
0.94 (95% CI: 0.88, 1.00); p = 0.043). Presence of underlying autoimmune disease was not predictive (HR 0.90224
(95% CI: 0.41, 1.95); p = 0.786).225
Global disease severity, as reported by clinicians and patients, is summarised (Figure 3, Figure 4). Self-reported226
pain gradually reduced during the first 6 weeks of treatment, and quality of life scores improved for both disease227
specific (DLQI) and general health status (EQ-5D-3L) questionnaires (Table 2). No covariates were predictive of228
scores at final visit for any of these outcomes, other than baseline scores for DLQI and EQ-5D VAS (DLQI estimate229
–0.47 (95% CI –0.77, –0.17); p = 0.003. EQ-5D VAS estimate –0.40 (95% CI: –0.65, –0.15); p = 0.003).230
Recurrence231
Of the 28 participants whose ulcer had healed, 27 had recurrence data available (minimum follow-up from232
time of healing 5.5 months; maximum follow-up 37.2 months). Overall 4/27 (14.8%) participants had a233
recurrence subsequent to their initial episode.234
Discussion235
Main findings236
This prospective cohort study of patients receiving topical therapy for the treatment of PG suggests that many237
patients with limited PG can be managed effectively with topical therapy alone. For almost half of the238
participants, healing was achieved within the 6-month study window and most of these had healed within 2239
months. This is similar to the proportions healed in the STOP GAP RCT, where again roughly half of the ulcers240
had healed by 6 months. Care should be taken when comparing healing rates between the RCT and the cohort241
study as participants in the RCT had more severe disease, as demonstrated by the increased number of ulcers,242
larger ulcer size at baseline, and greater impact on quality of life. Of those who failed to heal on topical therapy,243
one third subsequently received systemic therapy; suggesting that not all patients can be adequately treated244
with topical therapy alone.245
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The most important predictor of time to healing was size of the ulcer at presentation. This is consistent with246
previous findings10.247
Given the increased mortality risk for patients with PG compared to patients with inflammatory bowel disease248
and apparently healthy individuals,3 it is important to evaluate the role of topical therapies for the management249
of PG. Similar concerns about increased mortality and morbidity in bullous pemphigoid patients (that could be250
partly due to systemic therapies such as prednisolone), led to an RCT by Joly et al. who found that mortality was251
reduced in those treated with potent topical steroids compared to those receiving systemic steroids.11252
The potential impact of PG on patients’ quality of life is high. Baseline EQ-5D-3L scores of 0.59 (cohort study)253
and 0.48 (RCT) are comparable to patients with mild to severe heart failure; where EQ-5D-3L scores of 0.78 (SD254
0.18) to 0.51 (SD 0.21) respectively have been reported.12255
One of the objectives of this study was to maintain contact with potential trial participants in order to improve256
recruitment into the RCT. In this regard, the cohort study was extremely effective, and resulted in an additional257
13/121 (11%) patients being enrolled into the RCT. For trials of rare conditions, where the evidence base is258
limited, the added complexities and expense of running a parallel study of this kind can often be warranted.13259
Strengths and limitations260
This multi-centre study is much larger than any of the previously published prospective cohort studies of PG261
patients.4, 5, 14 Clinicians prescribed topical medication in line with local practice, but treatment allocations were262
not randomised. As a result, it is not possible to make formal comparison of different topical treatments such as263
corticosteroids versus tacrolimus. Data on sub-groups of patients are presented for interest, but should be264
interpreted cautiously. Tacrolimus may be an effective treatment for PG, but further evaluation in comparison265
to topical corticosteroids is required. Very little is known about the natural history of PG if left untreated. In the266
absence of placebo control arm, it is not possible to say whether or not the lesions would have healed without267
intervention, although clinical experience would suggest that this is unlikely.268
Generalisability269
This was a pragmatic study that reflected current practice. For an uncommon condition such as PG it was270
necessary to recruit across many hospitals, which aids the generalisabilty of the results. Nevertheless, this cohort271
of patients was recruited alongside an RCT of systemic treatments for PG and this may have impacted on the272
12
type of patients agreeing to take part. Patients with more severe disease were randomised into the RCT and273
those with milder or more localised disease entered the cohort study.274
Clinical conclusions275
Mild PG may be controlled effectively using topical agents without incurring the side-effects associated with276
systemic treatments. The importance of ulcer size on presentation in determining treatment response, and the277
relatively high recurrence rates are findings that will assist clinicians in optimising the management of PG, and278
in managing patients’ expectations with regards to the potential effectiveness of treatments.279
280
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Table 1: Baseline characteristics of participants in STOP GAP RCT and topical therapies cohort study
RCT Cohort study Cohort sub-groups
n= 112 n = 66
clobetasol
propionate
n=49
tacrolimus
n= 10
Demographics
Age: years Mean (SD) 54.4 (16.3) 57.3 (17.3) 57.5 (17.9) 53.0 (13.0)
Sex: n (%) Female 73 (65.2) 44 (66.7) 34 (69.4) 6 (60.0)
Ethnicity: n (%) White 108 (96.4) 64 (97.0) 47 (95.9) 10 (100.0)
Weight: kg Mean (SD) 90.7 (25.8) 80.4 (20.3) 77.8 (17.2) 86.2 (29.7)
Medical History
Underlying co-
morbidities: n (%)
Crohn’s Disease 8 (7.1) 6 (9.1) 2 (4.1) 2 (20.0)
Ulcerative colitis 15 (13.4) 8 (12.1) 7 (14.3) 1 (10.0)
Rheumatoid
arthritis 8 (7.1) 2 (3.0) 2 (4.1) 0 (0.0)
Other
inflammatory
arthritis
6 (5.4) 5 (7.6) 3 (6.1) 2 (20.0)
Monoclonal
gammopathy 0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0)
Myeloma 0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0)
Haematological
malignancy 0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0)
Other
malignancy 4 (3.6) 6 (9.1) 5 (10.2) 0 (0.0)
Diabetes 13 (11.6) 7 (10.6) 5 (10.2) 2 (20.0)
Renal
impairment 2 (1.8) 3 (4.5) 2 (4.1) 0 (0.0)
Epilepsy 1 (0.9) 1 (1.5) 1 (2.0) 0 (0.0)
Characteristics of PG
Type of PG: n (%)
Classical 97 (86.6) 55 (83.3) 43 (87.8) 9 (90.0)
Cribriform 6 (5.4) 1 (1.5) 0 (0.0) 0 (0.0)
Peristomal 4 (3.6) 6 (9.1) 3 (6.1) 1 (10.0)
Bullous 1 (0.9) 2 (3.0) 2 (4.1) 0 (0.0)
Unsure 4 (3.6) 2 (3.0) 1 (2.0) 0 (0.0)
Previous episode
of PG: Yes n (%) 31 (27.7) 18 (27.3) 12 (24.5) 3 (30.0)
Area of target
lesion: cm2
n 112 65 48 10
Median (Q1; Q3) 9.0 (3.2, 24.4) 4.7 (2.4; 11.0) 4.4 (1.6; 10.5) 6.8 [2.8, 11.0]
Location of
lesion: n (%)
Upper limb 3 (2.7) 7 (10.6) 6 (12.2) 0 (0.0)
Lower limb 75 67.0) 39 (59.1) 29 (59.2) 6 (60.0)
Other 34 (30.4) 20 (30.3) 14 (28.6) 4 (40.0)
Number of lesions
n=110 n = 65 (n = 48) (n=10)
Mean (SD) 2.4 (2.1) 1.6 (1.2) 1.6 (1.1) 1.8 (1.1)
n 112 66 49 10
Erytherma
n (%)
None 6 (5.4) 0 (0.0) 0 (0.0) 0 (0.0)
Slight 5 (4.5) 9 (13.6) 10 (20.4) 1 (10.0)
Moderate 36 (32.1) 10 (15.2) 15 (30.6) 8 (80.0)
Severe 39 (34.8) 32 (48.5) 16 (32.7) 1 (10.0)
Very Severe 26 (23.2) 15 (22.7) 8 (16.3) 0 (0.0)
n= 112 65 49 10
Border Elevation
n (%)
None 5 (4.5) 14 (21.5) 6 (12.2) 0 (0.0)
Slight 53 (47.3) 23 (35.4) 24 (49.0) 1 (10.0)
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Moderate 36 (32.1) 23 (35.4) 17 (34.7) 8 (80.0)
Severe 13 (11.6) 4 (6.2) 1 (2.0) 1 (10.0)
Very Severe 5 (4.5) 1 (1.5) 1 (2.0) 0 (0.0)
Exudate
n (%)
n= 112 66 49 10
None 4 (3.6) 8 (12.1) 9 (18.4) 0 (0.0)
Slight 16 (14.3) 13 (19.7) 12 (24.5) 1 (10.0)
Moderate 59 (52.7) 27 (40.9) 22 (44.9) 8 (80.0)
Severe 15 (13.4) 11 (16.7) 4 (8.2) 1 (10.0)
Very Severe 18 (16.1) 7 (10.6) 2 (4.1) 0 (0.0)
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Table 2: Treatment response (RCT participants and cohort participants)
Sub-groups
RCT participants
n=112
All cohort participants
n = 66
clobetasol propionate
n=49
tacrolimus
n= 10
Speed of healing n= 108 n = 54 n = 37 n = 10
Mean (SD) cm2/day -0.2 (0.8) -0.1 (0.3) -0.1 (0.2) -0.1 (0.1)
% healed by final visit
(up to 6 months)
n=112 n=64 n=47 n= 10
n (%) 53 (47.3) 28 (43.8) 20 (42.6) 5 (50.0)
Time to healing (days) n=112 n=64 n=47 n= 10
Median (95% CI) 169 days (113;∞) 145 days (96;∞) 136 days (46;∞) 161 days (13;∞)
Area of lesion: cm2 * n = 108 n=55 n=38 n= 10
Baseline: median (Q1; Q3) 9.0 (3.2; 24.8) 5.9 (1.8; 13.6) 6.4 (1.6; 14.0) 6.8 (2.8; 11.0)
Final visit: median (Q1; Q3) 0.0 (0.0; 8.1) 0.0 (0.0; 9.0) 0.0 (0.0; 9.0) 1.2 (0.0; 3.5)
Mean change from baseline at final visit (SD) -9.1 (51.1) -4.2 (11.5) -4.0 (11.9) -3.9 (6.0)
Median change (Q1; Q3) -5.0 (-15.8; -1.5) -3.4 (-8.7; -0.3) -1.7 (-7.4; -0.2) -3.3 (-8.5; -0.3)
Resolution of inflammation# n=107 n=54 n=49 n= 10
6 weeks: n (%) 11 (10.3) 8 (14.8) 6 (16.2) 0 (0.0)
n= 108 n=55 n=38 n=10
Final visit: n (%) 20 (18.5) 12 (21.8) 10 (26.3) 1 (10.0)
AUC for weekly pain in 1st six weeks (range 0 to 20);
high score = worse
n=77 n=37 n=24 n= 7
Mean (SD) 7.6 (5.2) 5.4 (5.2) 5.6 (5.2) 7.3 (6.3)
DLQI (range 0 to 30); high score = worse n = 111 n=66 n=49 n= 10
Baseline: mean (SD) 11.7 (8.2) 8.4 (6.0) 8.5 (6.0) 8.8 (4.6)
n = 66 n=49 n=32 n= 10
Final visit: mean (SD) 5.5 (7.2) 6.2 (6.8) 7.6 (7.5) 4.6 (5.4)
EQ-5D* (range 0 to 1); high score = better n=108 n= 66 n= 49 n= 10
Baseline: mean (SD) 0.48 (0.4) 0.59 (0.3) 0.60 (0.3) 0.51 (0.3)
n = 69 n= 51 n= 34 n= 10
Final visit: mean (SD) 0.71 (0.4) 0.69 (0.3) 0.65 (0.3) 0.73 (0.3)
EQ-5D VAS (range 0 to 100); high score = better n =110 n= 66 n= 49 n= 10
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Baseline: mean (SD) 62.0 (21.8) 67.0 (20.4) 65.6 (21.9) 64.4 (15.9)
: n = 70 n= 50 n= 33 n= 10
Final visit: mean (SD) 72.1 (21.2) 73.6 (20.5) 69.3 (22.2) 78.2 (13.1)
Recurrence (in those who had healed by 6 months)$ n=52 n=27 n=19 n= 5
n (%) 15 (28.8) 4 (14.8) 4 (21.1) 0 (0.0)
# Assessed by clinician, resolution of inflammation defined as erythema and border elevation reduced to “none” – as per Foss 7. $ Minimum follow-up after healing: RCT (0
to 40.3 months); cohort (5.5 months to 37.2), depending on when recruited. * Captures health utility based on responses (0 to 2) for mobility, self-care, usual activities,
pain/discomfort, anxiety/depression.
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Figure 1: Participant flow observational study
Screened for RCT / Observational
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Cohort Study (n=67)
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